secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001193125-25-026683
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta enters $600M senior secured revolving credit facility with JPMorgan as admin agent
--------------------------------------------------------------------------------

- Five-year $600M revolving credit facility closed Feb 13, 2025; variable interest at Adjusted SOFR + 1.125%-1.75% spread based on leverage.
- Financial covenants: max secured net leverage ratio 3.5:1.0 (4.0:1.0 holiday for acquisitions); min interest coverage ratio 2.5:1.0.
- Facility matures Feb 13, 2030; proceeds for general corporate purposes; secured by substantially all assets of obligors.
- Commitment fee on unused portion ranges from 0.20% to 0.35% per annum based on total gross leverage ratio.
- Lead arrangers include JPMorgan, Barclays, Citizens, Goldman Sachs, Morgan Stanley, and RBC as co-syndication agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312525026683/0001193125-25-026683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312525026683/d875089d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-026683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer